10:59 AM
 | 
Oct 26, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA grants Priority Review to Incyte's Jakafi for acute GvHD

Incyte Corp. (NASDAQ:INCY) said FDA accepted and granted Priority Review to an sNDA seeking approval for Jakafi ruxolitinib to treat acute graft-versus-host disease (GvHD) in patients with inadequate response to corticosteroids....

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >